Table 2.
Clinical features of patients treated with at least one experimental drug for COVID-19 versus not-treated patients.
| Treated Group | Non-Treated Group | p-Value | |
|---|---|---|---|
| n: 201 | n: 150 | ||
| Age (mean ± SD) | 53.38 ± 17.19 | 53.24 ± 17.22 | 0.999 |
| Male, n (%) | 115 (57.21%) | 78 (52%) | 0.33 |
| Smokers, n (%) | 12 (5.97%) | 7 (4.66%) | 0.59 |
| AF, n (%) | 10 (4.97%) | 1 (0.66%) | 0.02 |
| Dyslipidemia, n (%) | 33 (16.41%) | 11 (7.33%) | 0.01 |
| Hypertension, n (%) | 84 (41.79%) | 39 (26%) | 0.002 |
| Diabetes Mellitus, n (%) | 27 (13.43%) | 5 (3.33%) | 0.001 |
| CAD, n (%) | 12 (5.97%) | 2 (1.33%) | 0.02 |
| CKD, n (%) | 10 (4.97%) | 2 (1.33%) | 0.06 |
| COPD, n (%) | 51 (25.37%) | 33 (22%) | 0.46 |
| ACEIs/ARBs, n (%) | 70 (34.82%) | 24 (16%) | 0.0001 |
| Ca-antagonists, n (%) | 28 (13.93%) | 10 (6.66%) | 0.03 |
| Beta-blockers, n (%) | 41 (20.39%) | 18 (12%) | 0.03 |
| Amiodarone, n (%) | 1 (0.49%) | 0 | 0.39 |
| Antiplatelet drugs, n (%) | 38 (18.90%) | 9 (6%) | 0.0005 |
| Statins, n (%) | 45 (22.38%) | 13 (8.66%) | 0.0006 |
| Oral anticoagulants, n (%) | 12 (5.97%) | 0 | 0.002 |
| Insulin, n (%) | 10 (4.97%) | 2 (1.33%) | 0.06 |
| Oral hypoglycemic agents, n (%) | 20 (9.95%) | 2 (1.33%) | 0.001 |
| Ivabradine, n (%) | 4 (1.99%) | 0 | 0.08 |
AF, atrial fibrillation; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease, DCM, dilated cardiomyopathy; ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers.